Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1551-1556

  Hu, Xiaobo ^a,c   Wei, Hui ^a,d   Xiang, Laiman ^a   Chertov, Oleg ^b   Wayne, Alan S ^a,e   Bera, Tapan K ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF SOUTH CHINA   (China)

^d INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ADP ribosylation; Diphthamide synthesis; DNA methylation; Drug resistance; Epigenetic regulation

Indexed keywords

ADENOSINE DIPHOSPHATE; AZACITIDINE; CD22 ANTIGEN; DPH1 PROTEIN; MOXETUMOMAB PASUDOTOX; PEPTIDES AND PROTEINS; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOSINE DIPHOSPHATE RIBOSYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DPH1 GENE; GENE; GENE EXPRESSION; IMMUNOTOXICITY; KOPN 8 CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RNA METHYLATION; SEQUENCE ANALYSIS;

ADP-RIBOSYLATION; DIPHTHAMIDE SYNTHESIS; DNA METHYLATION; DRUG RESISTANCE; EPIGENETIC REGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BACTERIAL TOXINS; BLOTTING, WESTERN; CELL PROLIFERATION; DNA METHYLATION; EXOTOXINS; GENE SILENCING; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84886783613     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.005     Document Type: Article

References (39)

1. Pui C.H., Pei D., Campana D., Bowman W.P., Sandlund J.T., Kaste S.C., et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2011, 29:386-391.
2. Hunger S.P., Lu X., Devidas M., Camitta B.M., Gaynon P.S., Winick N.J., et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol 2012, 30:1639-1663.
3. Pastan I., Hassan R., Fitzgerald D.J., Kreitman R.J. Immunotoxin treatment of cancer. Annu Rev Med 2007, 58:221-237.
4. Pastan I., Hassan R., Fitzgerald D.J., Kreitman R.J. Immunotoxin therapy of cancer. Nat Rev Cancer 2006, 6:559-565.
5. Wayne A.S., Kreitman R.J., Findley H.W., Lew G., Delbook C., Steinberg S.M., et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: Preclinical studies and phase I clinical trial. Clin Cancer Res 2010, 16:1894-1903.
6. Ogata M., Chaudhary V.K., Pastan I., FitzGerald D.J. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000Da toxin fragment that is translocated to the cytosol. J Biol Chem 1990, 265:20678-20685.
7. Chiron M.F., Fryling C.M., FitzGerald D.J. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 1994, 269:18167-18176.
8. Hessler J.L., Kreitman R.J. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 1997, 36:14577-14582.
9. McKee M.L., FitzGerald D.J. Reduction of furin nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry 1999, 38:16507-16513.
10. Moehring T.J., Danley D.E., Moehring J.M. In vitro biosynthesis of diphthamide, studied with mutant Chinese hamster ovary cells resistant to diphtheria toxin. Mol Cell Biol 1984, 4:642-650.
11. Chen J.Y., Bodley J.W., Livingston D.M. Diphtheria toxin-resistant mutants of Saccharomyces cerevisiae. Mol Cell Biol 1985, 5:3357-3360.
12. Mattheakis L.C., Shen W.H., Collier R.J. D.P.H5 a methyltransferase gene required for diphthamide biosynthesis in Saccharomyces cerevisiae. Mol Cell Biol 1992, 12:4026-4037.
13. Mattheakis L.C., Sor F., Collier R.J. Diphthamide synthesis in Saccharomyces cerevisiae: structure of the DPH2 gene. Gene 1993, 132:149-154.
14. Greganova E., Altmann M., Bütikofer Unique modifications of translation elongation factors. FASEB J 2011, 278:2613-2624.
15. Schultz D.C., Balasara B.R., Testa J.R., Godwin A.K. Cloning and localization of a human diphthamide biosynthesis-like protein-2 gene, DPH2L2. Genomics 1998, 52:186-191.
16. Kantarjian H., Thomas D., Wayne A.S., O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 2012, 30:3876-3883.
17. Wei H., Xiang L., Wayne A.S., Chertov O., FitzGerald D.J., Bera T.K., et al. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc Natl Acad Sci USA 2012, 109:6898-6903.
18. Pastan I., Beers R., Bera T.K. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004, 248:503-518.
19. Du X., Beers R., Fitzgerald D.J., Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 2008, 68:6300-6305.
20. Zhang Y., Hansen J.K., Xiang L., Kawa S., Onda M., Ho M., et al. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res 2010, 70:1082-1089.
21. Du X., Nagata S., Ise T., Stetler-Stevenson M., Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 2008, 111:338-343.
22. Chaudhary V.K., Queen C., Junghans R.P., Waldmann T.A., FitzGerald D.J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989, 339:394-397.
23. Fei Z., Bera T.K., Liu X., Xiang L., Pastan I. Ankrd26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. J Biol Chem 2011, 286:27761-27768.
24. Du X., Youle R.J., FitzGerald D.J., Pastan I. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol 2010, 30:3444-3452.
25. Zhu X., Kim J., Su X., Lin H. Reconstitution of diphthine synthase activity in vitro. Biochemistry 2010, 49:9649-9657.
26. Hess C.J., Ameziane N., Schuurhuis G.J., Errami A., Denkers F., Kaspers G.J., et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 2008, 30:299-306.
27. Afonja O., Smith J.E., Cheng D.M., Goldenberg A.S., Amorosi E., Shimamoto T., et al. MEIS1 and HOXA7 genes in human acute myeloid leukemia. Leuk Res 2000, 24:849-855.
28. Vilas-Zornoza A., Agirre X., Martín-Palanco V., Martin-Subero J.I., San José-Eneriz E., Garate L., et al. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. PLoS ONE 2011, 6:e17012.
29. Ichikawa N., Kobayashi H., Saito H. Ph1-positive acute lymphoblastic leukemia in a patient with a germline MEN1 gene mutation. Int J Hematol 2003, 78:171-172.
30. Agirre X., Román-Gómez J., Vázquez I., Jiménez-Velasco A., Garate L., Montiel-Duarte C., et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 2006, 118:1945-1953.
31. Ohyashiki K., Fujieda H., Miyauchi J., Ohyashiki J.H., Tauchi T., Saito M., et al. Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3. Leukemia 1991, 5:322-3231.
32. Drexler H.G., Quentmeier H., MacLeod R.A. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia 2004, 18:227-232.
33. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat Genet 1999, 21:163-167.
34. Stone R.M. How I treat patients with myelodysplastic syndromes. Blood 2009, 113:6296-6303.
35. Strathdee G., MacKean M.J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999, 18:2335-2341.
36. Fulda S., Küfer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001, 20:5865-5877.
37. Worm J., Guldberg P. DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J Oral Pathol Med 2002, 31:439-443.
38. Morita S., Iida S., Kato K., Takagi Y., Uetake H., Sugihara K. The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology 2006, 71:437-445.
39. Ishiguro M., Iida S., Uetake H., Morita S., Makino H., Kato K., et al. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol 2007, 14:1752-1762.